The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | A Phase I study evaluating BAFF ligand-directed CAR T-cells with obinutuzumab in R/R CLL/SLL
Joseph Melenhorst, PhD, Cleveland Clinic, Cleveland, OH, outlines a Phase I study (NCT06916767) evaluating BAFF ligand-directed CAR T-cells (LMY-920) in relapsed/refractory (R/R) chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). The approach incorporates pre-apheresis obinutuzumab to improve T-cell yield and quality prior to CAR T-cell engineering. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
